MedTrace Logo

Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury

NCT01802996 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2040

Last updated 2013-10-30

No results posted yet for this study

Summary

This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.

Conditions

  • Neoplasms
  • Liver Injury

Interventions

DRUG

Magnesium Isoglycyrrhizinate Injection

200mg IV on day 1-5

Sponsors & Collaborators

  • Cttq

    lead INDUSTRY

Principal Investigators

  • Qin Shukui, MD · The 81st hospital of PLA

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802996 on ClinicalTrials.gov